Cucurbitacin-I induces hypertrophy in H9c2 cardiomyoblasts through activation of autophagy via MEK/ERK1/2 signaling pathway

被引:21
作者
Wu, Yao [1 ,2 ]
Chen, Hongying [2 ]
Li, Ruli [2 ]
Wang, Xiaoxiao [2 ]
Li, He [1 ]
Xin, Juanjuan [2 ]
Liu, Zhiqiang [2 ]
Wu, Sisi [2 ]
Jiang, Wei [2 ]
Zhu, Ling [1 ]
机构
[1] Sichuan Univ, Sch Preclin & Forens Med, Chengdu 610041, Peoples R China
[2] Sichuan Univ, West China Hosp, Mol Med Res Ctr, State Key Lab Biotherapy, Chengdu 610041, Sichuan, Peoples R China
基金
中国国家自然科学基金;
关键词
Cucurbitacin-I; Cardiomyocyte hypertrophy; MEK/ERK1/2; Autophagy; U0126; CANCER-THERAPIES; CELLS; APOPTOSIS; PROTECTS; INJURY;
D O I
10.1016/j.toxlet.2016.11.003
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Cucurbitacin-I, a natural triterpenoids initially identified in medicinal plants, shows a potent anticancer effect on a variety of cancer cell types. Nevertheless, the cardiotoxicity of cucurbitacin-I has not heretofore been reported. In this study, the mechanisms of cucurbitacin-I-induced cardiotoxicity were examined by investigating the role of MAPK-autophagy-dependent pathways. After being treated with 0.1-0.3 mu M cucurbitacin-I for 48 h, H9c2 cells showed a gradual decrease in the cell viabilities, a gradual increase in cell size, and mRNA expression of ANP and BNP (cardiac hypertrophic markers). CucurbitacinI concentration-dependent apoptosis of H9c2 cells was also observed. The increased apoptosis of H9c2 cells was paralleling with the gradually strong autophagy levels. Furthermore, an autophagy inhibitor, 3-MA, was used to block the cucurbitacin-I-stirred autophagy, and then the hypertrophy and apoptosis induced by 0.3 mu M cucurbitacin-I were significantly attenuated. In addition, cucurbitacin-I exposure also activated the MAPK signaling pathways, including ERK1/2, JNK, and p38 kinases. Interestingly, only the ERK inhibitor U0126, but not the JNK inhibitor SP600125 and p38 MAPK inhibitor SB203580, weakened the induction of 0.3 mu M cucurbitacin-I in hypertrophy, autophagy and apoptosis. Our findings suggest that cucurbitacin-I can increase the autophagy levels of H9c2 cells, most likely, through the activation of an ERK-autophagy dependent pathway, which results in the hypertrophy and apoptosis of cardiomyocytes. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:87 / 98
页数:12
相关论文
共 38 条
  • [1] Pharmacogenomics of metabotropic glutamate receptor subtype 1 and in vivo malignant melanoma formation
    Abdel-Daim, Mohamed
    Funasaka, Yoko
    Komoto, Mari
    Nakagawa, Yoko
    Yanagita, Emmy
    Nishigori, Chikako
    [J]. JOURNAL OF DERMATOLOGY, 2010, 37 (07) : 635 - 646
  • [2] Cardiotoxicity associated with cancer therapy: Pathophysiology and prevention strategies
    Adao, Rui
    de Keulenaer, Gilles
    Leite-Moreira, Adelino
    Bras-Silva, Carmen
    [J]. REVISTA PORTUGUESA DE CARDIOLOGIA, 2013, 32 (05) : 395 - 409
  • [3] Cucurbitacins - A Promising Target for Cancer Therapy
    Alghasham, Abdullah A.
    [J]. INTERNATIONAL JOURNAL OF HEALTH SCIENCES-IJHS, 2013, 7 (01): : 77 - 89
  • [4] Autophagy in Cell Life and Cell Death
    Anding, Allyson L.
    Baehrecke, Eric H.
    [J]. APOPTOSIS AND DEVELOPMENT, 2015, 114 : 67 - +
  • [5] A high-throughput AO/PI-based cell concentration and viability detection method using the Celigo image cytometry
    Chan, Leo Li-Ying
    Smith, Tim
    Kumph, Kendra A.
    Kuksin, Dmitry
    Kessel, Sarah
    Dery, Olivier
    Cribbes, Scott
    Lai, Ning
    Qiu, Jean
    [J]. CYTOTECHNOLOGY, 2016, 68 (05) : 2015 - 2025
  • [6] Intermedin Suppresses Pressure Overload Cardiac Hypertrophy through Activation of Autophagy
    Chen, HuaLi
    Wang, Xue
    Tong, MingMing
    Wu, Dan
    Wu, Sisi
    Chen, JiaXiang
    Wang, XiaoXiao
    Wang, XuLei
    Kang, Yu
    Tang, Hong
    Tang, ChaoShu
    Jiang, Wei
    [J]. PLOS ONE, 2013, 8 (05):
  • [7] Biological activities and potential molecular targets of cucurbitacins: a focus on cancer
    Chen, Xiuping
    Bao, Jiaolin
    Guo, Jiajie
    Ding, Qian
    Lu, Jinjian
    Huang, Mingqing
    Wang, Yitao
    [J]. ANTI-CANCER DRUGS, 2012, 23 (08) : 777 - 787
  • [8] Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines
    Curigliano, G.
    Cardinale, D.
    Suter, T.
    Plataniotis, G.
    de Azambuja, E.
    Sandri, M. T.
    Criscitiello, C.
    Goldhirsch, A.
    Cipolla, C.
    Roila, F.
    Grp, E. S. M. O. Guidelines Working
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 155 - 166
  • [9] Cardiotoxicity of Anticancer Treatments: Epidemiology, Detection, and Management
    Curigliano, Giuseppe
    Cardinale, Daniela
    Dent, Susan
    Criscitiello, Carmen
    Aseyev, Olexiy
    Lenihan, Daniel
    Cipolla, Carlo Maria
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2016, 66 (04) : 310 - 325
  • [10] Toxicity testing in the development of anticancer drugs
    Double, J
    Barrass, N
    Barnard, ND
    Navaratnam, V
    [J]. LANCET ONCOLOGY, 2002, 3 (07) : 438 - 442